Psoriasis trials recruiting in Kentucky

All Psoriasis trials nationally

Cities in Kentucky

Recruiting trials in Kentucky

• A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
  NCT06671496 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Kentucky: Bowling Green
• A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis
  NCT07489885 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · Kentucky: Louisville
• A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
  NCT06979453 · Phase: Phase 3 · Ages: 12 Years to 17 Years · Sex: All (male and female) · Kentucky: Murray
• A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
  NCT06857942 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · Kentucky: Bowling Green
• An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
  NCT07449702 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Kentucky: Bowling Green
• Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
  NCT07116967 · Phase: Phase 3 · Ages: 40 Years and older · Sex: All (male and female) · Kentucky: Bowling Green, Louisville, Owensboro
• Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry
  NCT02418442 · Phase: Not specified · Ages: Up to 21 Years · Sex: All (male and female) · Kentucky: Louisville
• Regulation of Mucosal Healing in Inflammatory Bowel Disease
  NCT04504136 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 90 Years · Sex: All (male and female) · Kentucky: Lexington
• Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
  NCT03816345 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Kentucky: Lexington